(Boursier.com) — GeNeuro a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and post-acute sequelae of COVID-19 (PASC , long COVID or post-COVID), announces the appointment of Anke Post, MD, PhD, as Chief Medical Officer, effective today, following the retirement of David Leppert, MD.
Professor David Leppert, Chief Medical Officer of GeNeuro since April 2020, has played a pivotal role in promoting temelimab as a neurodegeneration-focused drug candidate in multiple sclerosis and in launching GeNeuro’s post-COVID initiative. the society. After his retirement, he will continue as a consultant to support GeNeuro in its mission to introduce temelimab to MS patients. Temelimab aims to complement current treatments, which offer only minimal effect in preventing long-term disability in MS patients.
GeNeuro is very pleased to welcome Dr. Anke Post, who brings his extensive academic and medical experience in the field of neuroscience, psychiatry and neurology, as well as extensive experience in the pharmaceutical industry. Dr. Post has worked for 25 years developing drugs for psychiatric and neurodegenerative diseases, including ALS. She brings her drug development experience to all phases of development, including leading teams on international projects, contract research organizations, and managing interactions with regulatory authorities.
“We are delighted to welcome Anke to the GeNeuro team. His extensive expertise in psychiatry and neurology will significantly strengthen our capabilities to carry out our ambitious programs against post-COVID neuropsychiatric syndromes, against MS and against ALS, to bring our promising drug candidates to these underserved patient populations,” said Jesús Martin-Garcia, CEO of GeNeuro. “I would also like to express my gratitude to David for his strong commitment to GeNeuro, for all his achievements in the development of temelimab and for his unique expertise in the field of MS that he continues to bring as a consultant.”
Dr. Anke Post has extensive expertise and training in Neuroscience, Psychiatry and Neurology, with a career spanning over 25 years in academic research and pharmaceutical R&D. She studied medicine at the universities of Berlin, Vienna and Münster and received her doctorate in medicine from the University of Münster, Germany. She completed her internship and training in psychiatry, psychotherapy and neurology at the Max Planck Institute of Psychiatry in Munich and obtained her habilitation degree at the Ludwig Maximilian University of Munich.
Since joining the pharmaceutical industry, she has led drug development programs in these areas in the United States and abroad, spanning all stages of development. Her extensive experience in drug development has led her to successfully hold key leadership positions in various multinational pharmaceutical, biotechnology and medical device companies, including Novartis, Eli Lilly, Roche, Idorsia and, most recently, UniQure .